Clinical Trials Logo

Clinical Trial Summary

The objectives of this study are to evaluate the immune response and safety profiles of two injections of EV71 vaccine administrated with or without adjuvant Al(OH)3 at 0.5-μg and 1-μg dose in children aged 3 to 6 years old and 2 to 35 months old infants/toddlers.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03268083
Study type Interventional
Source Enimmune Corporation
Contact
Status Completed
Phase Phase 2
Start date July 2016
Completion date December 2017

See also
  Status Clinical Trial Phase
Completed NCT04091880 - Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine Phase 4
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Completed NCT01313715 - A Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Phase 1
Enrolling by invitation NCT05099029 - A Study to Evaluate the Efficacy, Immunogenicity and Safety of an EV71 Vaccine in Healthy Infants and Children Phase 3
Completed NCT00426699 - Urinary Excretion of Enteroviruses From Children With a Presumed Enteroviral Infection N/A
Recruiting NCT06263439 - Surveillance of HFMD in Pediatric Outpatients
Completed NCT05016687 - First-in-human Clinical Trial Evaluating CUR-N399 in Healthy Volunteers. Phase 1
Terminated NCT01129232 - Diabetes Virus Detection Project, Intervention With GAD-alum Phase 2
Recruiting NCT04431050 - Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
Active, not recruiting NCT04769167 - Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes N/A
Completed NCT02777411 - A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old Phase 2
Withdrawn NCT04535648 - Detection of Enterovirus Genotypes by CRISPR Technology